24 April 2013 | News | By BioSpectrum Bureau
Daiichi Sankyo, Ranbaxy to leverage synergies in Thailand
Singapore: Japan's Daiichi Sankyo and Ranbaxy Laboratories have plans to integrate their business operations in Thailand, to leverage and maximize the synergies of the Hybrid Business Model, which is expected to commence business on April 1, 2013.
The planned integration of operations will provide a strong foundation for future Daiichi Sankyo Group business expansion in Thailand. The development will be mutually beneficial to Ranbaxy and Daiichi Sankyo. It is expected to enhance their competitiveness while offering both innovative and affordable, high quality generic medicines to the people of Thailand as well as generate cost synergies for both companies.
Under this strategy, Daiichi Sankyo and Ranbaxy would integrate the management of Daiichi Sankyo's subsidiary in Thailand, Daiichi Sankyo (Thailand) Ltd. (DSTH) and Ranbaxy's Thailand subsidiary, Ranbaxy Unichem Co., Ltd. (RUCL). The new representative of the proposed integrated entity will be Suthas Thongprasert, who presently heads DSTH.